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The IκB kinase (IKK) complex acts as the gatekeeper of canonical NF-κB signaling, thereby regulating 
immunity, inflammation and cancer. It consists of the catalytic subunits IKKα and IKKβ and the 
regulatory subunit NEMO/IKKγ. Here, we show that the ubiquitin binding domain (UBAN) in NEMO 
is essential for IKK/NF-κB activation in response to TNFα, but not IL-1β stimulation. By screening a 
natural compound library we identified an anthraquinone derivative that acts as an inhibitor of NEMO-
ubiquitin binding (iNUB). Using biochemical and NMR experiments we demonstrate that iNUB binds 
to NEMOUBAN and competes for interaction with methionine-1-linked linear ubiquitin chains. iNUB 
inhibited NF-κB activation upon UBAN-dependent TNFα and TCR/CD28, but not UBAN-independent 
IL-1β stimulation. Moreover, iNUB was selectively killing lymphoma cells that are addicted to chronic 
B-cell receptor triggered IKK/NF-κB activation. Thus, iNUB disrupts the NEMO-ubiquitin protein-
protein interaction interface and thereby inhibits physiological and pathological NF-κB signaling.
NF-κ B signaling plays a crucial role in inflammation, immune responses, survival and cell proliferation1. The 
canonical NF-κ B signaling can be activated through various pathways including TNF receptor (TNFR), IL-1 
receptor (IL-1R) or T-cell receptor (TCR)2,3. Upon ligand binding, proximal signaling events converge at the Iκ B 
kinase (IKK) complex, which acts as the gatekeeper of NF-κ B signaling by phosphorylating and inactivating the 
inhibitors of NF-κ B (Iκ Bs).
The IKK complex consists of two catalytic subunits IKKα /IKKβ and the regulatory subunit IKKγ /NEMO 
(NF-κ B essential modulator)4. The IKK regulatory subunit NEMO serves as a critical integrating platform that 
couples upstream receptor signaling complexes to the catalytic IKKs5,6. Biochemical and genetic studies have high-
lighted a pivotal function of poly-ubiquitination for IKK/NF-κ B activation. It has been shown that IKK upstream 
signaling adaptors like RIP1 (TNFR), IRAK1/4 (IL-1R) or MALT1 (TCR) are modified by ubiquitin (Ub) chains 
to recruit NEMO and thereby promote IKK activation2,7,8. Assembly of Met1-linked (linear) Ub chains by the 
LUBAC (linear Ub assembly complex) is also essential for IKK/NF-κ B activation in response to various stimuli9–12.
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The Ub binding surface in NEMO called UBAN (Ub binding in ABIN and NEMO) has been co-crystallized 
with linear as well as with K63 Ub chains13,14. Despite the fact that the NEMO C-terminus comprising the UBAN 
and the zinc finger (ZF) domain has a high preference for binding to linear Ub chains, it can also bind K63 or K11 
chains15–18. The importance of non-covalent NEMO-Ub interaction for delivering upstream signaling events in 
response to TNFR, IL-1R or TCR/BCR stimulation to activate the IKK complex has been highlighted by several 
studies19. Moreover, chronic B-cell receptor (BCR) signaling in the aggressive activated B-cell (ABC) subgroup of 
diffuse large B-cell lymphoma (DLBCL) has been shown to require regulatory ubiquitination and the LUBAC20,21. 
Overexpression of the NEMOUBAN or cell permeable peptides comprising the UBAN or leuzine zipper (LZ) regions 
interfered with ubiquitin association or NEMO oligomerization and impeded NF-κ B activation22–24. Thus, disrup-
tion of NEMO-ubiquitin binding may be a promising strategy to inhibit inducible physiological as well as chronic 
pathological NF-κ B activation.
In this work, we demonstrate by direct comparative analyses that UBAN-dependent NEMO-ubiquitin interac-
tion is required for NF-κ B in response to TNFα , but not IL-1β stimulation. We identified an inhibitor of NEMO-Ub 
binding (iNUB), an anthraquinone derivative of the natural product Emodin, as a small molecule that binds to the 
NEMOUBAN. Using biochemical, biophysical and NMR experiments we show that iNUB acts as a protein-protein 
interaction (PPI) inhibitor by preventing the recruitment of linear Ub chains. Consistent with the genetic data, 
iNUB inhibits TNFα , but not IL-1β -triggered NF-κ B signaling. iNUB interferes with antigen receptor signaling 
to NF-κ B and acts toxic in human lymphoma cells that are addicted to chronic BCR signaling.
Results
Differential requirement of NEMOUBAN for TNFα and IL-1β-induced NF-κB signaling. The critical 
role for the binding of Ub chains to the NEMOUBAN motif has been demonstrated by multiple NEMO mutations 
that either directly prevent NEMO-Ub binding or indirectly disturb the structural conformation of the coiled-
coil2/leucine-zipper (CC2-LZ) region13,17,25. Mutations in NEMO were shown to impair IKK/NF-κ B activation 
after TNFα and IL-1β stimulation13,26. However, the requirement of the UBAN and other regions in NEMO for 
TNFα and IL-1β -induced NF-κ B signaling has not been directly compared. We used NEMO deficient mouse 
embryonic fibroblasts (NEMO−/Y MEFs) that were reconstituted with NEMO WT or NEMO mutants (Fig. 1a). 
The co-expressed surface marker human ΔCD2 was used for sorting homogenous populations of infected cells 
(> 90%) that expressed NEMO proteins at equivalent levels (Supplementary Fig. 1a–d)18. Whereas NEMO WT 
was able to efficiently rescue defective NF-κ B signaling in response to TNFα or IL-1β stimulation as reflected by 
Iκ Bα phosphorylation and degradation, as well as activation of NF-κ B DNA binding, deletion of the IKK inter-
action surface (ΔIKK; Δ44–111) abolished NF-κ B signaling (Supplementary Fig. 1e–g)27. The deletions ΔCC1-1 
(Δ112–150) and ΔCC1-2 (Δ151–223) in NEMO did not interfere with IKKα /β association and led to a par-
tial or complete inhibition of both TNFα and IL-1β signaling to NF-κ B, respectively (Supplementary Fig. 1e–g). 
Similarly, deletion of the linker region between CC1 and CC2 encoded by exon5 (Δ224–257) reduced NF-κ B 
activation in response to both inducers (Fig. 1b,c). In contrast to these mutations, removal of the CC2 (Δ259–304) 
or the Ub binding region in the UBAN (Δ296–327) prevented NF-κ B signaling in response to TNFα , but only par-
tially diminished IL-1β -triggered NF-κ B activation (Fig. 1b,c). Moreover, the NEMOUBAN point mutation D311N 
or the deletion of the C-terminal zinc finger (E391X: Δ391–417), two patient derived mutations that cause anhi-
drotic ectodermal dysplasia with immunodeficiency (EDA-ID), abolished TNFα -induced NF-κ B signaling, but 
only mildly affected IL-1β stimulated NF-κ B activation (Fig. 1d,e). Thus, while the NEMO CC2, UBAN and ZF in 
the C-terminus are essential for TNFα signaling, these domains are largely dispensable for IL-1β signaling, empha-
sizing that distinct NEMO surfaces are required for bridging the different receptor pathways to canonical NF-κ B.
Structural characterization of the NEMOUBAN dimer and linear Ub2 in solution. To explore the 
possibility of small molecule inhibition to interfere with protein-protein interaction (PPI) of NEMOUBAN and 
ubiquitin, we first addressed the stoichiometry and conformation of NEMOUBAN alone and in complex with linear 
Ub2 (linUb2) in solution. Whereas a 2:2 stoichiometry had been reported for the NEMOUBAN:linUb2 complex in 
co-crystals (PDB 2ZVO)13, a 2:1 stoichiometry was described in solution25. Indeed, by size exclusion chromatog-
raphy (SEC) in combination with static light scattering (SLS) we found that one NEMOUBAN dimer associates with 
one linear Ub2, revealing a 2:1 stoichiometry for the complex (Supplementary Fig. 2a,b).
To gain further insight into the structure of the NEMOUBAN:linUb2 complex, we performed small angle X-ray 
scattering (SAXS) experiments using NEMOUBAN C347S (258–350). Microscale Thermophoresis (MST) and 
Isothermal Titration Calorimetry (ITC) measurements confirmed that the C347S mutation in NEMO does not 
affect the affinity (KD ~ 1–2 μ M) and the 2:1 stoichiometry of the NEMOUBAN:linUb2 complex (Supplementary 
Fig. 2c,d)18,25. SAXS data also revealed that NEMOUBAN forms a dimer in solution (Supplementary Fig. 2e and 2b). 
However, the relatively high χ 2 value indicates that the solution conformation of NEMOUBAN is slightly different 
from the crystal structure (PDB 3FX0)25, suggesting that NEMOUBAN in solution is not strictly linear. Comparison 
of the SAXS experimental curves for Ub2 with the theoretical curves back-calculated from the two published crystal 
structures for linear Ub2 suggests that the solution conformation of linear Ub2 is better represented by an ensemble 
of an open (PDB 3AXC)28 and a compact (PDB 2W9N)29 domain arrangements seen in previous crystal structures 
with 38%:62% population (Supplementary Fig. 2f). Calculated Porod volumes and MWs from the scattering curves 
obtained for solutions containing NEMOUBAN C347S and linear Ub2 at ratios of 2:1 and 2:2 (Fig. 2a,b) are consistent 
with a complex of two NEMOUBAN molecules (i.e. one NEMO dimer) bound to one linear Ub2. A DAMMIF model 
derived from the SAXS data of the 2:1 NEMOUBAN:Ub2 solution showed an elongated surface with only one hump 
consistent with an NEMO dimer bound to one Ub2 in solution (Fig. 2c).
We used Nuclear Magnetic Resonance (NMR) experiments to analyze the NEMOUBAN binding interface to 
linear Ub2 in solution and compared it with the previously reported crystal structure13. We could assign 84% of 
the backbone NMR signals of NEMOUBAN (258–350) and analyzed spectral changes induced upon the addition 
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of unlabeled linear Ub2 in a 2:1 ratio (NEMOUBAN:Ub2) (Fig. 2d). Chemical shift perturbations were observed for 
multiple amino acids on NEMO that are directly contacting linear Ub2 in the crystal, e.g. V300, A303, Q304, D311, 
E324, E320. However, additional shifts were obtained for several residues distributed across the entire CC2-LZ 
region of NEMO that are not directly involved in contacting linear Ub2 (Fig. 2e). Taken together, the SAXS and 
NMR data suggest that, in solution, binding of linear Ub2 to NEMOUBAN induces allosteric effects that modulate 
the overall structure and dynamics of the NEMOCC2-LZ dimer. Such allosteric effects could also explain that only 
an asymmetric 2:1 complex is formed as allosteric changes induced by binding of one Ub2 molecule may prevent 
binding of a second Ub2 moiety on the opposite surface.
Identification of NEMO-Ub binding inhibitors from a natural compound library. Due to the rela-
tively low binding affinity of NEMOUBAN to ubiquitin (KD 1–2 μ M for linear and 12–130 μ M for K63 Ub2)13,15,18,25, 
the conformational dynamics of the NEMOUBAN (see Fig. 2) and the selective requirement of the NEMOUBAN for 
TNFα , but not IL-1β signaling to NF-κ B (see Fig. 1), we wanted to test whether NEMO-Ub interaction could be 
susceptible to small molecule inhibition. We used the previously established ‘Dissociation-Enhanced Lanthanide 
Fluorescent Immunoassay’ (DELFIA) technology to detect binding of recombinant Myc-NEMOUBAN-StrepTagII 
(aa 246–350) and His-linUb2 in a multi-plate format (Supplementary Fig. 3a)18. As expected, linear Ub2 bound 
Figure 1. NEMO-Ub binding is essential for TNFα signaling, but not for IL-1β signaling. (a) Schematic 
illustration of NEMO deletions or point mutations. (b,c) Effects of NEMO C-terminal deletion mutants on 
TNFα and IL-1β signaling. NEMO−/Y MEFs were reconstituted with mock, NEMO WT or different C-terminal 
deletion constructs and stimulated with TNFα (b) or IL-1β (c). Effects on NF-κ B signaling were investigated 
by determining Iκ Bα phosphorylation and degradation in Western Blots as well as NF-κ B-DNA binding by 
EMSA. (d,e) Effects of NEMO D311N on TNFα and IL-1β signaling. NEMO−/Y MEFs were reconstituted with 
mock, NEMO WT or NEMO D311N point mutant and stimulated with TNFα (d) or IL-1β (e). Analysis on 
NF-κ B signaling were performed as in (b,c).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:18934 | DOI: 10.1038/srep18934
to NEMOUBAN and association was abrogated by the UBAN mutation D311N (Supplementary Fig. 3b). We 
screened a small molecule library of 320 purified natural products for their ability to inhibit binding of linUb2 
to NEMOUBAN (Supplementary Fig. 3c). The screening provided robust signal to noise ratio (Z’ factor 0.78) and 
delivered 4 hits, which significantly reduced the signal for NEMO-Ub binding below 50% (Supplementary Fig. 3d). 
One of the compounds that most severely reduced the signal was a derivative of the anthraquinone Aloe-Emodin. 
Anthraquinones like Emodin and Aloe-Emodin are natural products, found as active ingredients in Chinese herbs, 
with demonstrated multiple biological effects including anti-inflammatory and anti-cancer activities30. Since 
Emodin affects several molecular pathways including NF-κ B signaling30, we wanted to test, if distinct anthraqui-
nones could affect the association of NEMO and ubiquitin. We tested the Aloe-Emodin derivative, Emodin as well 
as 10 other chemically synthesized anthraquinones for their ability to inhibit the interaction of NEMO and linear 
Ub2 in DELFIA (Supplementary Fig. 3e). Interestingly, whereas most anthraquinones including Emodin did not 
significantly inhibit NEMO-Ub2 binding, Aloe-Emodin derivative and anthraquinone 1 (8-hydroxy-9,10-dioxo-9,
10-dihydro-1-anthracenyl 2-phenylcyclopropanecarboxylate) were able to significantly inhibit this interaction.
iNUB disrupts NEMO-Ub interaction by binding to NEMOUBAN. To investigate the potential impact 
of distinct anthraquinones on NEMO-Ub binding, we determined the effects of the most effective inhibitor, i.e. 
anthraquinone 1, which we henceforth call inhibitor of NEMO-Ub binding (iNUB). In DELFIA, iNUB disrupted 
NEMOUBAN interaction to linUb2 with an EC50 of 9.3 μ M and even though it was not able to completely block the 
interaction, it reduced the signal more than 70% at 40–80 μ M (Fig. 3a).
Figure 2. The NEMO-Ub2 complex has a 2:1 stoichiometry in solution. (a) The 2:1 stoichiometry of the 
NEMO-Ub2 complex is supported by comparison of the SAXS experimental curves with theoretical curves 
back-calculated from either the 2:2 NEMO-Ub2 co-crystal structure (PDB 2ZVO, 2:2) or a 2:1 complex, where 
one Ub2 was removed from the crystal structure. (b) The calculated MWs in the table show that independent 
of the mixing ratio of NEMOUBAN and Ub2 a 2:1 complex is formed, and (c) the 2:1 ratio is further supported 
by the shape of the envelope of ab initio modeling with DAMMIF (shown in yellow). (d) NMR analysis of the 
NEMOUBAN-linUb2 interaction. 1H,15N TROSY NMR spectrum of 100 μ M 15N-labeled NEMO in the absence 
(black) or presence of Ub2 (red) in a 2:1 (NEMOUBAN:Ub2) ratio. Amides, which disappear upon Ub2 addition 
are indicated. (e) Mapping of the backbone amides, which disappear upon linUb2 addition in panel d onto the 
NEMOUBAN surface from the crystal structure (PDB 2ZVO).
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We used NMR titrations to confirm that iNUB was able to compete the binding of linUb2 to NEMOUBAN. NMR 
experiments recorded with 15N-labeled linUb2 in the absence (orange) or presence (blue) of unlabeled NEMOUBAN 
C347S (Fig. 3b) show large spectral changes upon binding of NEMO (NEMOUBAN : Ub2 1:1). Consistent with a 
previous study (Fig. 3b)25, many Ub2 backbone amide NMR signals show a significant intensity reduction upon 
addition of NEMOUBAN, due to severe line broadening. Mapping of the Ub2 backbone amide resonances with 
strongest changes onto the crystal structure of NEMO-Ub2 (PDB 2ZVO) highlights the Ub2 interface on NEMO 
Figure 3. The small molecule iNUB inhibits binding of NEMOUBAN to linUb2. (a) DELFIA assay detection 
of StrepTagII-NEMOUBAN (242–350) binding to His-tagged linUb2 with or without iNUB. Increasing iNUB 
concentrations disrupted binding of NEMO to linUb2 binding with an EC50 of 9.26 μ M. (b) NMR analysis of the 
NEMOUBAN-linUb2 interaction. 1H, 15N HSQC spectra of 100 μ M 15N-labeled linUb2 in absence (orange) and in 
presence of unlabeled NEMOUBAN C347S (258–350) (blue) at 1:1 stoichiometry. (c) Backbone amide resonances 
of Ub2 resonances showing strongest changes upon NEMOUBAN addition are annotated and indicated as spheres 
on the NEMO crystal structure (PDB 2ZVO). Red spheres indicate residues with unambiguous chemical shift 
assignments, while orange color shows amides, which could not be unambiguously assigned to the proximal 
or distal Ub moieties or showing signal overlap. Gray spheres are the amides of the corresponding residues in 
the other Ub module. (d) 1H, 15N HSQC spectra of 100 μ M 15N-labeled Ub2 bound to the NEMOUBAN (1:1) 
in the presence of DMSO (blue) or 290 μ M iNUB (red). NMR signals of linUb2 residues that showed reduced 
signal intensity upon binding to NEMOUBAN are partially restored upon treatment with iNUB. (e) Mapping of 
Ub residues that show strongest effects upon iNUB addition onto the NEMOUBAN structure as in (d). (f) Ratio 
of amide peak volume upon iNUB versus DMSO addition for the 15N-labeled Ub2 complexed with unlabeled 
NEMO (1:1 stoichiometry).
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and the essential role of many Ub2 amino acids in contacting NEMOUBAN, which are confirmed by mutagenesis 
(Fig. 3c)25.
Next, we compared the chemical shifts of 15N-labeled linUb2 when bound to NEMOUBAN (1:1) in the presence 
of DMSO or iNUB to test whether the addition of iNUB can compete with the NEMO-Ub2 interaction (Fig. 3d–f). 
Indeed, iNUB induced the reappearance of many linUb2 signals that were reduced upon NEMO binding. Notably, 
many of these residues have been previously shown to have a critical role in the NEMOUBAN and Ub2 interaction 
based on the crystal structure and/or mutagenesis, e.g. R42, V70 and L73 in the distal Ub moiety and F4, T12 and 
I13 in the proximal Ub moiety13,25.
In addition, we determined the effects of Emodin, because many studies suggested that Emodin is able to impair 
NF-κ B signaling30. Confirming our previous results, Emodin did not significantly affect NEMO-Ub2 binding up 
to 20 μ M and slightly reduced binding by approximately 25% at 80 μ M (Supplementary Fig. 4a). As expected, 
incubation of 15N-labeled linUb2-NEMOUBAN complex (1:1) with Emodin resulted in fewer changes in chemical 
shifts of Ub2 amino acids, validating DELFIA results that Emodin exerts only a very mild effect on the NEMO-Ub 
interaction (Supplementary Fig. 4b–d).
To determine the mechanism of how iNUB disrupts NEMO-linUb2 interaction, we performed MST to elucidate 
to what component iNUB is binding (Fig. 4a). Titration of increasing iNUB concentrations to fluorescence-labeled 
NEMOUBAN or linUb2 revealed that iNUB induced a change in thermophoresis only with NEMOUBAN. Thus, 
iNUB directly binds to NEMO with a KD of ~2.14 μ M, which is in the affinity range of NEMO-linUb2 interaction 
(Supplementary Fig. 2c,d)25. iNUB did not show any binding to linUb2 in MST assays. Consistent with these data, 
we did not detect significant chemical shifts on 15N-labeled linUb2 upon incubation with iNUB reflecting that 
iNUB is not binding to Ub2 (Fig. 4b).
Figure 4. iNUB binds and alters the conformation of the NEMOUBAN. (a) Microscale Thermophoresis (MST) 
assays to determine binding of iNUB to NEMOUBAN or linUb2. iNUB binds to Myc-NEMOUBAN-ZF-StrepTagII 
(242–350) with a KD of 2.14 μ M. (b) 1H,15N HSQC spectra of 50 μ M 15N-labeled linUb2 in the absence (black) 
and presence of 1 mM iNUB (red). (c) NMR analysis of the NEMOUBAN-iNUB interaction. 1H,15N TROSY NMR 
spectrum of 117 μ M 15N-labeled NEMOUBAN (258–350) with DMSO (black) or 870 μ M iNUB (red). Amide 
signals that are affected upon iNUB addition are indicated. Asterisks indicate unassigned NMR signals that are 
affected by iNUB. (d) Mapping of residues affected upon iNUB addition onto the NEMOUBAN crystal structure 
(PDB 2ZVO).
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We used 15N-labeled NEMOUBAN WT (see Fig. 2) to verify a direct binding of iNUB to NEMOUBAN by NMR 
(Fig. 4c). iNUB binding induced a number of changes in the NEMOUBAN spectrum. We mapped the residues 
affected by iNUB incubation onto the crystal structure (Fig. 4d). A number of backbone amide NMR signals 
exhibit small chemical shifts and an increase in the intensity of NMR signals upon addition of iNUB. Similar to 
linUb2 addition (compare Fig. 2d,e), affected residues were not localized to one spot in the UBAN, but scattered 
throughout the NEMOUBAN dimer. For some of the affected residues, a critical involvement in binding to ubiquitin 
or maintenance of the NEMOUBAN coiled-coil structure has been demonstrated previously. For example, Q304 
establishes hydrophobic interactions with V70 and L8 of the distal Ub2 moiety13. Q304 also forms a hydrogen bond 
to D306 that stabilizes the dimer and the mutation Q304A weakens NEMO-Ub2 interaction17,25. Furthermore, 
A323 is involved in preserving the α -helical structure and, the Incontinentia Pigmenti (IP) associated mutation, 
A323P completely distorts dimerization and thereby indirectly abrogates Ub binding17,25. Thus, just like binding of 
linUb2, iNUB alters the conformational dynamics of the NEMOCC2-LZ and induces changes in amino acids within 
the NEMOUBAN that are directly involved in binding to Ub and/or preserving the dimer interface. Thereby, iNUB 
can prevent the formation of the NEMOUBAN:linUb2 complex.
iNUB inhibits UBAN-dependent NF-κB activation upon TNFα and TCR/CD28 stimulation. To 
test if iNUB is affecting NEMOUBAN dependent NF-κ B activation upon cell stimulation, we treated MEFs with 20 
or 40 μ M of iNUB before stimulation with TNFα or IL-1β (Fig. 5a,b). In the experimental setup, iNUB did not 
show cell toxicity up to concentrations of 60 μ M as revealed in viability assays (Supplementary Fig. 5). Equivalent 
to the requirement for NEMOUBAN, iNUB reduced Iκ Bα phosphorylation/degradation and NF-κ B DNA bind-
ing in response to TNFα in a dose dependent manner, while it did not significantly affect IL-1β induced NF-κ B 
signaling (Fig. 5a,b). To evaluate inhibitor selectivity, we determined activation of the MAPK JNK in MEFs in 
response to TNFα and IL-1β after iNUB treatment (Fig. 5c,d). Here, iNUB did not significantly affect TNFα or 
IL-1β stimulated JNK phosphorylation, showing that the compound is selectively acting on the NF-κ B signaling 
pathway in response to TNFα .
Emodin, which was only mildly competing for NEMO-Ub binding in vitro also impaired Iκ Bα phosphoryla-
tion/degradation as well as NF-κ B DNA binding in response to TNFα , but not IL-1β stimulation (Supplementary 
Fig. 6a,b). However, cellular effects were considerably weaker when compared to iNUB treatment. Importantly, 
Emodin was also more selective in targeting TNFα triggered NF-κ B signaling and IL-1β was not affected 
(Supplementary Fig. 6b).
We determined induction of NF-κ B target gene activation after iNUB treatment (Fig. 5e,f). Whereas induction 
of TNFAIP3/A20, ICAM-1 and VCAM-1 transcripts were decreased by iNUB after TNFα stimulation (Fig. 5e), 
expression of TNFAIP3/A20 and ICAM-1 target genes upon IL-1β stimulation was not severely affected by iNUB 
(Fig. 5f). Also, Emodin impaired TNFAIP3/A20, ICAM-1 and VCAM-1 expression after TNFα stimulation 
(Supplementary Fig. 6c), but again to a lesser extent than iNUB. Congruent with the anti-apoptotic function 
of NF-κ B, induction of apoptosis was elevated in TNFα treated cells either in the presence of iNUB or more 
weakly by incubation of Emodin, revealing that diminished NF-κ B activation renders the cells more susceptible 
to TNFα -triggered cell death (Fig. 5g and Supplementary Fig. 6d).
Next, we investigated whether iNUB acts upstream of IKK activity in MEFs after TNFα stimulation (Fig. 5h,i). 
For this, we performed IKK kinase assays, after the cells have been treated with 20 or 40 μ M of iNUB. The IKK 
complex was enriched by NEMO co-immunoprecipitation and IKK activity was measured in an in vitro kinase 
reaction. TNFα -induced IKK activation was markedly reduced in cells pre-treated with iNUB (Fig. 5h). To validate 
that iNUB is not acting directly on IKK kinases, but rather acts upstream on TNFα stimulation dependent IKK 
activation, we repeated the experiment in MEFs, but instead of treating the cells, we added iNUB in increasing 
concentrations to the precipitated IKK complex before the in vitro kinase reaction (Fig. 5i). In this case, iNUB 
was unable to inhibit IKK activity. Moreover, in contrast to a pharmacological IKKβ active site inhibitor, iNUB 
was not able to reduce activity of recombinant IKKβ in a pure in vitro kinase assay (Fig. 5j). Hence, inactivation of 
cellular IKK activity by iNUB is not due to a direct inhibition of IKK kinase activity, but rather a disturbed signaling 
upstream of the IKK complex in response to TNFα signaling.
To verify that iNUB affects NEMO UBAN dependent recruitment of Ub modified proteins in cells, we used 
NEMO−/Y MEFs reconstituted with StrepTagII-NEMO WT or the UBAN mutant D311N (Fig. 5k). In agreement 
with previous results31, polyubiquitinated RIP1 was co-precipitated by StrepTactin pull-down (ST-PD) of NEMO 
WT after TNFα stimulation and association required an intact UBAN as it was lost in NEMO D311N expressing 
cells. In the same experimental setup, iNUB treatment (20 and 40 μ M) of NEMO WT MEFs also inhibited asso-
ciation of NEMO to ubiquitinated RIP1 (Fig. 5l). Thus, similar to UBAN mutations, iNUB treatment prevented 
stimulation dependent recruitment of NEMO to ubiquitinated RIP1, suggesting that the inhibitor disconnects the 
IKK complex from upstream regulators.
The NEMOUBAN domain was also found to be essential for IKK/NF-κ B activation in response to TCR/CD28 
co-stimulation18. To determine if iNUB affects T-cell activation, we tested iNUB on NF-κ B signaling and target gene 
expression in primary murine CD4+ T-cells stimulated with anti-CD3/CD28 antibodies (Fig. 6). Treatment with 
iNUB inhibited Iκ Bα phosphorylation upon TCR/CD28 co-engagement of CD4+ T-cells (Fig. 6a). iNUB treatment 
led to a dose-dependent decrease in the induction of the NF-κ B target genes IL-2, TNFAIP3/A20, NFKBIA/Iκ Bα 
and IFNγ (Fig. 6b,c). Induction of IL-2 secretion was also markedly reduced by iNUB as determined by ELISA 
(Fig. 6b). Thus, iNUB also impaired NEMOUBAN-dependent TCR/CD28 NF-κ B signaling in primary CD4+ T-cells.
iNUB is selectively toxic to IKK/NF-κB dependent ABC-DLBCL. The survival of ABC-DLBCL 
tumor cells relies on constitutive NF-κ B activation driven by oncogenic mutations and/or chronic BCR sign-
aling upstream of the IKK complex32. IKKβ inhibitors are well-documented to selectively kill ABC-DLBCLs33 
and, thus we wanted to determine whether iNUB also affected pathological NF-κ B signaling that results from 
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Figure 5. Inhibition of TNFα induced NF-κB signaling by iNUB. (a,b) Effects of iNUB on TNFα and 
IL-1β -induced NF-κ B signaling. MEFs were treated with 20 μ M and 40 μ M iNUB or DMSO 6 h before stimulation 
with TNFα (a) or IL-1β (b). NF-κ B signaling was investigated by determining Iκ Bα phosphorylation and 
degradation in Western Blot and NF-κ B activation by EMSA. (c,d) iNUB does not affect JNK activation. MEFs were 
treated with DMSO or iNUB (40 μ M) 6 h prior to stimulation with TNFα (c) or IL-1β (d). Phosphorylation of JNK 
and total JNK were analyzed by Western Blotting. (e,f) iNUB inhibits NF-κ B target gene expression after TNFα , 
but not IL-1β stimulation. MEFs were treated with 20 μ M and 40 μ M iNUB or DMSO and stimulated with TNFα 
(e) or IL-1β (f). mRNA was isolated and NF-κ B target genes were investigated by qRT-PCR. (n = 3; + /− SD) (g) 
iNUB induces apoptosis after TNFα stimulation. MEFs were stimulated for 24 h in the presence or absence of iNUB. 
Apoptosis was analyzed by AnnexinV staining and FACS. (n = 3; + /− SD) (h) iNUB impairs TNFα -induced IKK 
activation. MEFs were treated with 20 μ M and 40 μ M iNUB before TNFα stimulation. IKK activity after NEMO IP 
was determined by in vitro kinase assay using GST-Iκ Bα 1–72 as the substrate. (i,j) iNUB does not directly inhibit 
IKK activity. The cellular IKK complex after TNFα stimulation and following NEMO IP (i) or recombinant IKKβ (j) 
were treated with iNUB before in vitro kinase reaction. IKKβ inhibitor (SC-514) served as positive control. (k) TNFα 
dependent recruitment of NEMO to ubiquitinated RIP1 via UBAN. ST-PD of StrepTagII-NEMO WT and D311N 
expressing MEF. Co-precipitation of ubiquitinated RIP1 in unstimulated or TNFα stimulated cells was performed 
and analyzed by Western Blot. (l) iNUB impairs recruitment of NEMO to ubiquitinated RIP1. ST-PD was performed 
with StrepTagII-NEMO WT after TNFα stimulation in the presence and absence of iNUB. Co-precipitated 
ubiquitinated RIP1 was analyzed by Western Blot.
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uncontrolled antigen signaling in these lymphoma cells. NF-κ B is necessary for maintenance of high expression 
level of anti-apoptotic and pro-inflammatory factors in ABC-DLBCL, and therefore we evaluated by qPCR the 
relative mRNA expression levels of a panel of NF-κ B target genes (c-FLIP, BclXL, TNFAIP3/A20, TNFα , NFKBIA/
Iκ Bα , IL-6, IL-10 and JunB) in the ABC-DLBCL cell lines HBL-1, OCI-Ly3, TMD8 and RIVA (Fig. 7a). Despite 
some variations in the extent of inhibition of the different target genes, treatment of iNUB markedly reduced the 
expression of NF-κ B regulated genes in ABC-DLBCL cells.
Since survival of ABC-DLBCL cells relies on constitutive NF-κ B signaling, we determined the effects of 20 and 
40 μ M iNUB treatment on ABC-DLBCL survival by counting of viable cells. To monitor selectivity, we also meas-
ured viability in NF-κ B independent germinal center B-cell (GCB) type of DLBCL cells lines (Fig. 7b). Whereas 
ABC-DLBCL cell lines HBL-1, OCI-Ly3, TMD8 and RIVA were sensitive to iNUB treatment and died in a time 
and dose-dependent manner, iNUB1 was not toxic to the GCB-DLBCL cells SudHL-4, SudHL-6 and BJAB. We 
confirmed the results by MTT assays as a second test for cellular viability (Fig. 7c). Again, only ABC-DLBCL cells 
but not GCB-DLBCL showed a dose-dependent induction of cell toxicity after iNUB treatment. Since NF-κ B inhi-
bition was shown to primarily enhance spontaneous apoptosis in ABC-DLBCL33, we determined iNUB dependent 
apoptosis. Indeed, apoptosis was increased by iNUB in ABC but not in GCB-DLBCL cells at 20 and 40 μ M (Fig. 7d) 
again illustrating the selectivity of treatment. Finally, to verify that iNUB decreased viability of ABC-DLBCL by 
acting upstream of IKKβ , we lentivirally reconstituted HBL-1 cells with a constitutively active IKKβ (caIKKβ ) 
mutant that drives canonical NF-κ B signaling independent of upstream events34. While in mock infected HBL-1 
cells the number of viable cells decreased by 40–50% after 4 days of iNUB treatment, expression of caIKKβ pro-
moted a strong resistance to iNUB-induced cell death (Fig. 7e). Thus, iNUB selectively inhibited NF-κ B activation 
in ABC-DLBCL and thereby counteracted cell survival and enhanced apoptosis.
Discussion
Developing small molecule inhibitors that target PPIs is a challenging task, because the contact surfaces are usually 
flat and large (~1500–3000 Å2), contain many hydrophobic residues and largely lack distinct pockets for optimal 
small molecule binding35,36. In this study, we have demonstrated that PPI inhibition can be a novel small molecule 
strategy to inhibit IKK activation and thus canonical NF-κ B signaling. We found that the anthraquinone derivative 
iNUB binds to the IKK regulatory subunit NEMO and, thereby alters NEMO dynamics to reduce its interaction 
with linear Ub2. In contrast to most PPI surfaces that have been targeted by small molecules, the NEMO-Ub binding 
interface does not contain distinct pockets, but is composed of extended α -helices forming a dimer. Interaction 
of the NEMOUBAN and linUb2 is of relatively low affinity25, which can facilitate the disruption by small molecule 
compounds. Based on NMR, SAXS and biophysical analyses we propose that iNUB acts through modulating the 
Figure 6. iNUB diminished NF-κB activation in murine T-cells after TCR/CD28 stimulation. (a) Inhibition 
of TCR/CD28 induced NF-κ B signaling by iNUB. Primary murine CD4+ T-cells were incubated with iNUB 
(20 μ M, 40 μ M) or DMSO and co-stimulated with anti-CD3/anti-CD28 antibodies. Iκ Bα phosphorylation 
was detected by Western Blotting. (b,c) iNUB inhibits NF-kB target gene expression in primary T-cells. CD4+ 
T-cells were treated as in (a,b) IL-2 expression was analyzed on mRNA level by qPCR after 3 h as well as on 
protein levels by ELISA after 20 h and (c) TNFAIP3/A20, TNFα , NFKBAI/Iκ Bα and INFγ mRNA expression 
was analyzed after 3 h (n = 3; + /− SD).
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structure and/or dynamics of the α -helical arrangement of the CC2-LZ region, as an unexpected and unique mode 
of action for small molecule inhibitors. We confirmed in cells that iNUB is acting on the level of the IKK complex, 
but not through direct targeting of catalytic IKKβ , as other conventional ATP-binding pocket inhibitors37. In line 
Figure 7. iNUB is toxic to ABC- but not GCB-DLBCL cells. (a) iNUB inhibits expression of NF-κB target 
genes in ABC-DLBCL cell lines. ABC-DLBCL cells (HBL-1, OCI-Ly3, TMD8, RIVA) were treated with iNUB 
(20 μ M) for 24 h and NF-κ B target genes were analyzed by qRT-PCR (n = 3; + /− SD). (b,c) Selective toxicity 
of iNUB in ABC- and GCB-DLBCL cells. ABC or GCB (SUDHL-4, SUDHL-6, BJAB) DLBCL cells were 
treated with single dose of 20 μ M or 40 μ M iNUB or DMSO. (b) Viable cells were counted after trypan blue 
exclusion over a period of 4 days (n = 4; optional representative experiment) or (c) MTT assay after 3 days of 
treatment (n = 4; + /− SD). (d) Apoptosis in ABC but not GCB-DLBCLs was induced by iNUB. Apoptotic cells 
were determined by Annexin-V staining of YO-PRO-3 negative cells and analyzed by FACS (n = 3; + /− SD). 
(e) Reduced viability of HBL-1 cells after iNUB treatment was rescued by expression of caIKKβ . HBL-1 cells 
expressing transduced with caIKKβ or mock were treated with iNUB (20 μ M) and relative viable cells numbers 
was determined by trypan blue exclusion over 4 days. Expression of caIKKβ was determined by Western 
Blotting (n = 3; + /− SD).
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with the in vitro data on disrupted UBAN-Ub binding, iNUB inhibits UBAN dependent recruitment of NEMO 
to poly-ubiquitinated RIP1, a process that was shown to be critical for TNFα induced IKK/NF-κ B activation7,8. 
iNUB did not inhibit activation of JNK, providing evidence that the compound is selectively impairing NF-κ B 
signaling in response to TNFα . Further, congruent with the genetic data on the role of the UBAN, iNUB inhibited 
NF-κ B signaling in response to TNFα and TCR/CD28 stimulation18, but did not affect UBAN-independent IL-1β 
stimulation (see also below). Also in ABC-DLBCL, a well-defined cancer entity whose survival relies on chronic 
activation of the BCR-IKK-NF-κ B axis, iNUB inhibited NF-κ B activity and selectively killed the tumor cells just 
like conventional IKKβ inhibitors33. Importantly, various studies have demonstrated the necessity of the LUBAC 
complex and linear ubiquitination for active BCR signaling20,21,38 thereby defining the molecular basis for iNUB 
inhibition in ABC-DLBCL.
The critical role of Ub binding to the NEMOUBAN for IKK activation has been demonstrated by structural 
studies13,14,17,25. Moreover, inactivating point mutations within the UBAN and adjacent regions are causing IP in 
females and EDA-ID in males39, revealing that small alterations within this region exert strong effects on activation 
of NF-κ B signaling. Indeed, we demonstrated by NMR that iNUB directly binds to the CC2-LZ region of NEMO 
and induces a number of chemical shift perturbations and resonance intensity changes. Some of these changes 
include residues that have been shown to be directly involved in Ub binding or NEMO dimerization13,17. However, 
other perturbations throughout the entire CC2-LZ region include residues in NEMO that are not expected to 
be involved in direct contacts with Ub2 and go far beyond the direct interactions mapped in the co-crystals13. 
Importantly, similar results were obtained when the interaction of linUb2 with NEMOCC2-LZ was analyzed using 
NMR. These data suggest that many chemical shift perturbations observed are not caused by the direct binding of 
either iNUB or linUb2 to specific amino acids, but rather reflect that iNUB or linUb2 disturbs the α -helical structure 
and dynamics of the NEMO dimer to provoke these extensive changes. Moreover, the conformational alterations 
may also be important for activation of IKKβ 40. Importantly, the structural and biophysical data suggest that iNUB 
is inducing similar, but less severe changes to the NEMOCC2-LZ dimer as linUb2. Thus, iNUB seems to allosterically 
alter the structural conformation and dynamics of the NEMOUBAN in a way that prevents its binding to linear Ub2.
Also, the widespread changes may explain the obvious discrepancy in the NEMOUBAN:Ub2 stoichiome-
try between the co-crystals and in solution assays. We confirmed the previously observed 2:1 stoichiometry of 
NEMOUBAN:Ub2 in solution25. Using SAXS data we could build a DAMMIF model showing a structure that best 
fits to the 2:1 NEMO stoichiometry of the NEMOUBAN:Ub2 complex. This complex is not symmetric as described 
for the crystal, but linUb2 is forming a hump and covering exclusively one side of the NEMO dimer. Together with 
the extensive spectral changes throughout the CC2-LZ seen in NMR, these data indicate that, in solution, binding 
of linUb2 to one side of the NEMO dimers precludes the interaction of a second Ub2 to the opposing surface. Thus, 
the 2:2 stoichiometry in the co-crystal may be induced by the crystal packing13.
In cells, iNUB is inhibiting TNFα , but not IL-1β driven NF-κ B signaling. By direct comparison in a well-defined 
reconstitution system, we provide evidence that the NEMOUBAN mutant D311N is required for NF-κ B activation 
in response to TNFα , but largely dispensable for IL-1β stimulation. Moreover, even the removal of the UBAN 
or the C-terminal ZF domain of NEMO only partially impaired IL-1β signaling to NF-κ B, despite the fact that it 
abrogated TNFα stimulation. In contrast, several N-terminal deletions resulted in equivalent decreases in NF-κ B 
activation after TNFα or IL-1β treatment, ruling out a general variation within the experimental system. Given the 
pivotal role of Ub conjugation for IKK activation in all NF-κ B signaling pathways, we were surprised to see such 
differences, and previous studies have reported decreased NF-κ B activation in cells with NEMOUBAN or NEMOZF 
mutations after IL-1β stimulation13,26,41–43. Zhang et al. reported severely reduced IKK activation after IL-1α stim-
ulation in MEFs from NEMOD311N/Y knock-in mice26. However, no direct comparison for the requirement of the 
NEMOUBAN for NF-κ B activation between TNF and IL-1 stimulation was performed. Interestingly, NF-κ B signaling 
was reduced in fibroblasts from human EDA-ID patients carrying NEMO D311G mutations in response to TNFα 
and IL-1β , but in both cases there was still considerable NF-κ B activation observed41. Thus, cell-specific and maybe 
even signal-specific (e.g. IL-1α versus IL-1β ) variations may contribute to differential requirements of NEMO 
domains to trigger IKK/NF-κ B in response to different stimuli. In fact, also the amount of NEMO is highly critical 
for signal propagation18. To minimize cell variability, we used reconstituted NEMO−/Y MEFs and worked with 
FACS sorted cell pools that express equivalent NEMO amounts. Also other studies found fundamental differences 
in NEMO-dependent processes to NF-κ B after TNFα and IL-1β stimulation. NEMOUBAN displays a > 100 fold 
higher affinity for M1 versus K63 Ub213,17,25 and an Ub replacement strategy provided evidence for a requirement 
of K63-linked ubiquitination in IL-1β , but not for TNFα signaling44. In line with this, IL-1β -triggered recruitment 
of NEMO to supramolecular clusters required K63-linked Ub chains, whereas it did not for TNFα stimulation45. 
Also, cysteine-to-serine substitutions in the C-terminal ZF of NEMO have been shown to affect IKK activation in 
response to TNFα , but not IL-1β 46. Even though we cannot fully resolve the discrepancies to some of the previous 
publications, our NEMO reconstitution provide clear evidence for differences in the requirement of C-terminal 
NEMO UBAN and ZF domains in the TNFα and IL-1β response. Congruent with our genetic complementation 
analyses, iNUB inhibited IKK/NF-κ B activation and target gene expression in response to TNFα stimulation, but it 
did not affect IL-1β signaling in cells. Thus, small molecules that interfere with the binding of NEMO to Ub chains 
can be a strategy to selectively impair certain signaling pathways without affecting NF-κ B response to other stimuli.
The potential of modulating Ub binding properties of the NEMO UBAN was previously shown by generating 
cell permeable peptides comprising the N-terminal part of the UBAN (UBI peptide)22. The UBI peptide contains 
the D311R, which impairs binding to Ub chains. However, mechanistically it was shown to bind to NEMO, thereby 
competing for Ub association and impairing NF-κ B signaling after LPS or TNFα stimulation. Interestingly, in 
contrast to iNUB the UBI peptide only prevents association of K63-linked chains, while not affecting the binding 
of linear poly-Ub. Further, the steroidal lactone Withaferin A (WA) was shown to inhibit NF-κ B signaling and to 
modulate NEMO-Ub binding properties of NEMO in cells and in vitro47,48. In contrast to iNUB, WA is covalently 
attached to the NEMOZF, causing a gain-of-function that selectively enhances binding of NEMO to K48-linked 
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Ub chains. However, how this impacts NF-κ B signaling is currently unclear and it was also shown that WA can 
inactivate IKKβ directly by targeting Cys179 in the kinase domain49.
iNUB belongs to the class of anthraquinones that comprise natural products and the pharmacologically active 
ingredients of Chinese herbs. Most studied is the anthraquinone Emodin, whose anti-inflammatory and anti-cancer 
activity is well-established30. Emodin affects multiple pathways including NF-κ B signaling, but the exact molecular 
targets are largely unresolved. Compared to iNUB, Emodin is a much weaker inhibitor of NEMO-Ub interaction 
and it is also less potent in inhibiting TNFα -triggered NF-κ B activation and target gene expression. However, 
despite the mild effects on NF-κ B signaling, Emodin still severely impacted on NF-κ B target gene expression and 
apoptosis induction. Thus, our data indicate that Emodin may not primarily act on upstream signaling, but also 
seems to inhibit NF-κ B activity further downstream, e.g. at the transcriptional level. Most likely also the pharma-
cological effects of iNUB will not only be restricted to prevention of NEMO-Ub binding, but we provide evidence 
that this mode of action contributes to NF-κ B inhibition and downstream effects. Thus, our data provide a proof 
of concept that it is possible to dissect the cellular targets of these naturally-derived products and to optimize their 
activity, which may be of interest for future therapeutic approaches.
Methods
Reagents. TNFα (50435; Biomol Germany); IL-1β (211-11B; PeproTech); antibodies: anti-Iκ Bα (sc-371, 
Santa Cruz, USA), anti-p-Iκ Bα (9246; Cell Signaling), anti-NEMO (FL-419, Santa Cruz), anti-β Actin (sc-1616, 
Santa Cruz), anti-IKKβ (05–535; Millipore), anti-IKKα (14A231; Imgenex), anti-JNK1/2 (9252; Cell Signaling), 
anti-p-JNK1/2 (9251; Cell Signaling), anti-Rip1 (3493; Cell Signaling) anti-FLAG M2 (F3165, Sigma); anti-mCD3 
(553057, BD Biosciences); anti-hCD28 (553294, BD Biosciences); anti-IgG (307-005-003, Dianova). Tris-d11 
(CD4035P1, Cortecnet); DL-dithiothreitol-d10 (CD570P1, Cortecnet); D2O (151882, Aldrich); DMSO-d6 
(156914, Aldrich); 15NH4Cl (CN80P100, Cortecnet); D-glucose 13C6 (CC860P20, Cortecnet); D-glucose 13C6-d7 
(CCD860P20, Cortecnet).
Cell Culture. DLBCL cell lines were cultured as previously described50. Mouse embryonic fibroblasts (MEF), 
NEMO−/Y MEFs, reconstituted NEMO−/Y MEFs and HeLa cells were cultured in DMEM supplemented with 10% 
FCS and 1% Pen/Strep. All cells were cultured in an H2O-saturated atmosphere with 5% CO2 at 37 °C.
Stimulation and Western Blot. MEF cells were treated with the indicated amounts of iNUB or DMSO for 
6 hours. Subsequently, MEF or HeLa cells were stimulated with 8 ng/ml TNFα or 1 ng/ml IL-1β . Murine primary 
T-cells were stimulated with mCD3/mCD28 (BD Biosciences) and hamster IgG antibodies (Dianova) on plates 
for 3 hours (qRT-PCR analysis) and 20 hours (ELISA analysis), respectively. DLBCL cell lines were treated with 
iNUB for 24h before cells were lysed for Western Blot analysis. Western blotting was carried out as described 
earlier51.
Electrophoretic Mobility Shift Assay (EMSA). For EMSA analysis, MEF cells were pre-
treated with iNUB or DMSO for 6 hours and stimulated with 8 ng/ml TNFα or 1 ng/ml IL-1β for sev-
eral time points. EMSA was performed as described previously52. Briefly, cells were lysed and 2 μ g 
of protein extract were incubated with a 32P-dATP–labeled, double-stranded NF-κ B oligonucleo-
tide probe (5′-CAGGGCTGGGGATTCCCCATCTCCACAGG-3′ ) or OCT1 oligonucleotide probe 
(5′-TGTCGAATGCAAATCACTAGAA-3′ ) and separated on native polyacrylamide gel electrophoresis before 
autoradiography.
Production of NEMO for biophysical and structural studies. For screening, the NEMO258–350 con-
struct was cloned, expressed and purified from E. coli strain BL2118. For other biochemical and biophysical meas-
urements NEMO258–350 or NEMO258–350 C347S were cloned into pET vectors containing a 3C or TEV protease 
cleavable N-terminal His6-tags. Details on purification and removal of epitope tags by proteolytic cleavage are 
given in the Supporting Information.
Microscale Thermophoresis (MST). Recombinant proteins were produced as described earlier using 
E. coli strain BL21-CodonPlus (DE3) RILP (Stratagene) and the pIBA3plus expression system (IBA GmbH, 
Göttingen, Germany). MST assays were mainly carried out as previously described18. Serial dilutions of iNUB 
or Emodin were incubated with NT647-labeled NEMOUBAN-ZF proteins for 30 minutes. MST assays were meas-
ured in a NanoTemper Monolith NT.115. Compound concentrations were plotted against percent changes of 
normalized fluorescence (ΔFnorm [%]), curve fitting was done with GraphPad Prism software and KD values were 
determined.
Small angle X-ray scattering (SAXS) analysis. SAXS measurements were performed on a Rigaku 
BIOSAXS1000 instrument with a HF007 microfocus generator equipped with a Cu-target at 40 kV and 30 mA. 
Transmissions were measured with a photodiode beamstop, q-calibration was made by an Ag-behenate measure-
ment. Measurements were done in four 900 second frames, which were averaged. In these conditions no radia-
tion damage was detected. Circular averaging and background subtraction was done with the Rigaku SAXSLab 
software v 3.0.1r1. Fits were made with crysol, ensembles with EOM, and distance distribution functions with 
GNOM, as provided with the ATSAS package v 2.5.0-253. Molecular weights were calculated from the Porod 
Volumes. Three-dimensional ab initio models were generated using the DAMMIF software53.
SAXS measurements were made at 293 K with the following concentrations, NEMOUBAN C347S four con-
centrations between 2.8 and 9.9 mg/ml, linear Ub2 five concentrations in the range of 0.9 to 9.9 mg/ml and three 
concentrations each for the 2:1 and the 2:2 complex in the range of 3.5 to 12.9 and 4.9 to 12.1 mg/ml respectively. 
The buffer contained 300 mM NaCl and 50 mM Tris-HCl at a pH of 8.0. No concentration dependent effects were 
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detected. Agreement of SAXS theoretical curves back-calculated from published crystal structures to experimental 
curves was evaluated by χ2 values.
NMR Spectroscopy. All NMR spectra were recorded on a Bruker AvanceIII 800 MHz spectrometer 
equipped with a TCI cryogenic or TXI room temperature probe head equipped with field gradient coils. All data-
sets were processed using NMRPipe54. Details for NMR spectroscopy are given in the Supplement.
DELFIA Assay. Recombinant proteins were produced as described for MST assays. 20 pmol of StrepII-tagged 
NEMO proteins (UBAN domain) in DELFIA assay buffer (PerkinElmer) were bound to StrepTactin coated plates 
(IBA GmbH) and unbound proteins were removed after 2 h incubation by washing. Subsequently, bound NEMO 
proteins were incubated with several concentrations of iNUB or Emodin for 30 minutes before adding 125 pmol 
His-linUb2 in DELFIA assay buffer for further 2 h incubation. Again, unbound proteins were removed after the 
incubation time by washing. Finally, 500 ng/ml europium-labeled anti-His-tag antibody was added and incubated 
for 1 h. After extensive washing enhancer solution (PerkinElmer Life Sciences) was added and the signal was 
measured in a PerkinElmer Envision plate reader (excitation, 340 nm; emission, 615 nm).
Viability, MTT and Apoptosis Assays. Viability, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) and Apoptosis Assays were carried out as described earlier50. Briefly, DLBCL cell lines 
were incubated with iNUB or DMSO in the indicated final concentrations for 24 hours. MEF cells were pretreated 
for 6 hours with iNUB or DMSO, respectively, before cells were stimulated with 8 ng/ml TNFα . Cell viability 
was analyzed by counting cells after trypan blue staining or by MTT cytotoxicity testing always in comparison 
to DMSO-treated control cells. Apoptosis rates were determined with Annexin-V-FITC staining of YO-PRO-3 
negative cells (BD Pharmingen) after 24 hours of compound treatment in DLBCL and MEF cells. For FACS anal-
ysis an LSRII flow cytometer (BD) was used, and data were analyzed with FlowJo software (Treestar). Viability 
of mock (GFP) and caIKKβ -GFP expressing cells in response to iNUB treatment was determined by counting 
trypan blue stained cells.
Lentiviral transduction. Cloning of hΔCD2-T2A-NEMO constructs into lentiviral vector, viral pro-
duction, transduction of MEFs and sorting of hΔCD2 positive cells was performed as described previously18. 
Expression of constitutively active Flag-IKKβ (caIKKβ ) mutant (SS176, 180EE) was conducted as described50. 
pLVTHM (Addgene plasmid # 12247), psPAX2 (Addgene plasmid # 12260) and pMD2.G (Addgene plasmid # 
12259) were a gift from Didier Trono55.
Quantitative qRT-PCR. cDNA generated from DNA-free RNA samples by reverse transcription was ana-
lyzed using LC-480 SybrGreen PCR mix (Roche) on a LC480 II Lightcycler system (Roche). 1 μ g RNA was tran-
scribed with Superscript II (Invitrogen) according to the manufacturer’s protocol, using random hexamers, with a 
final RNase H digestion step. The qRT-PCR experiments after TNFα stimulation were performed as described18, 
while qRT-PCR experiments in murine primary cells were carried out as described previously50. Quantification of 
NF-κ B target genes were done with RNA PolII as control. All primer sequences are in the supplement.
In vitro Kinase Assays. MEF cells were either pre-treated with iNUB before stimulation with TNFα or 
pre-stimulated with TNFα following a post-treatment with iNUB of the precipitated active IKK complex. In both 
cases IKKβ activity was investigated after immunoprecipitation (IP) of the IKK complex using an anti-NEMO 
antibody. Subsequently, recombinant GST-Iκ Bα (aa 1–72) was added to the precipitated IKK complex and the 
activity was analyzed by detection of pIκ Bα in Western blot assays. Co-IP and Western blotting was done as 
described previously52. Recombinant active IKKβ was incubated with iNUB or an IKKβ inhibitor (sc-514, Santa 
Cruz) for 30 minutes. Subsequently, GST-Iκ Bα was added and pIκ Bα was analyzed by Western Blotting.
Detection of cellular interaction of NEMO and ubiquitinated RIP1. NEMO−/Y MEF cells were 
transduced with StrepTagII-tagged constructs (mock, NEMO wildtype and NEMO D311N). Cells were grown 
in 150 mm cell culture plates until 90% confluence. Cells were either left untreated or treated with DMSO/
iNUB for 6 hours and subsequently stimulated with 10ng/mL TNFα . Afterwards cells were lysed in 500 μ l 
lysis buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 0.2% NP-40, 10% glycerol, 1 mM DTT, 10 mM sodium flu-
oride, 8 mM β -glycerophosphate, 300 μ M sodium vanadate and protease inhibitor cocktail) and StrepTactin 
pull-down (ST-PD) was performed by adding StrepTactin sepharose (IBA lifesciences) and incubating overnight. 
Co-precipitated RIP1 ubiquitination was detected in Western Blot analysis using RIP1 D94C12 antibody from 
cell signaling.
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